Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Significant Drop in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 37,100 shares, a decline of 45.2% from the December 15th total of 67,700 shares. Currently, 2.8% of the company’s shares are short sold. Based on an average daily trading volume, of 307,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 1.95% of the stock is owned by institutional investors and hedge funds.

Sonoma Pharmaceuticals Trading Up 0.8 %

Shares of SNOA traded up $0.02 on Tuesday, reaching $2.60. 13,565 shares of the company’s stock were exchanged, compared to its average volume of 42,419. Sonoma Pharmaceuticals has a 12 month low of $2.44 and a 12 month high of $9.37. The stock has a market capitalization of $3.48 million, a P/E ratio of -0.52 and a beta of 1.41. The business has a 50 day moving average price of $2.74 and a two-hundred day moving average price of $2.10.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.